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Abstract.  
Thirty years ago, 3.4-methylendioxymethamphetaime or MDMA was a novel 
psychoactive substance (NPS), and since then empirical knowledge of its 
psychobiological effects in humans has increased substantially. It is now known that 
recreational users can suffer from a wide range of psychobiological deficits, in 
neurocognition, memory, information processing, vision, pain, oxidative stress 
immunocompetence, neurohormonal integrity, sleep, homeostasis, and psychiatric 
well-being. Functional deficits may remain after several years of abstinence.  Ten 
years ago mephedrone was a novel psychoactive substance, and recent studies have 
generated some limited knowledge about its psychobiological effects, although many 
areas of uncertainly remain. This review will outline current scientific knowledge on 
each drug, and suggest areas for future research. One crucial area is the effects of 
mephedrone on human pregnancy, since taking MDMA during pregnancy can impair 
subsequent child development.      
 
Introduction. 
 
This paper is an extended version of a keynote paper given at the European 
Conference on Novel Psychoactive Substances (NPS), held at the Fielder Centre in 
Hertfordshire University, on November 15th-16th 2016. The conference was funded by 
the European Union, with the aim of disseminating the latest information on the 
clinical, pharmacological, psychosocial, legal and other aspects of the many new 
psychoactive drugs being used across Europe and the world.  My own paper focused 
on current extensive knowledge about the psychobiology of recreational MDMA, and 
a comparison with the more limited empirical knowledge on mephedrone. One key 
aim was to illustrate how our theoretical understanding about MDMA had increased 
dramatically over the past 15 years, since research had revealed many novel areas of 
psychobiological deficit. The main focus of my talk was the empirical research 
conducted by my research group at the University of East London (pre-2004), then at 
Swansea University (2004-present), and latterly as a visiting Professor to the Centre 
for Human Psychopharmacology in Melbourne (2008-present). However research 
findings from many other groups were also covered. Recently we have undertaken 
comparative studies with established stimulants such as cocaine (1), and 
methamphetamine (2). This paper will conclude with two empirical comparisons 
between recreational Ecstasy/MDMA and mephedrone (3,4). The aim was to 
investigate the similarities and differences in their psychobiological profiles, and 
propose topics for future research. 
 
MDMA or ‘Ecstasy’: a broad overview 
 
MDMA or 3,4-methylenedioxymethamphetamine, is a methamphetamine derivative 
and powerful CNS stimulant.  It first became popular as a recreational drug during the 
mid-1980s, when it was given the street name of ‘Ecstasy’ (5-8). Around that  time 
MDMA was a ‘novel psychoactive substance’, although that particular label was not 
employed for another twenty years. In one of the first descriptions of its 
psychopharmacological effects, Shulgin (9) suggested that MDMA would not become 
a psychosocial drug of abuse, since it lost its subjective efficacy when taken 
repeatedly. However despite its strong chronic tolerance, many recreational users 
followed a pattern of increasing self-dosing, accompanied by stronger and more 
damaging side-effects (10,11). The deteriorating cost-benefit ratio with MDMA leads 
to voluntary drug cessation – an unusual and possibly unique pattern for any 
psychoactive drug (11-14). This pattern helps to explain why MDMA is not often 
seen as a drug of dependency. However, while many users quit on their own, other 
young Ecstasy/MDMA users still need professional help from drug addiction centres 
(15-17).    
 
In acute terms, MDMA is powerful metabolic activator, which causes increased body 
temperature in thermally controlled laboratory conditions (18,19). It can lead to 
greater thermal stress and hyperthermia in dance clubbers, although there can be 
considerable variation in these thermal changes in the real world (20, 21, 90). In cold 
conditions recreational users may cool-down excessively, so when returning from 
night clubs in Wintery conditions, some users become hypothermic with adverse 
medical consequences (23,24). The Hypothalamic Pituitary Adrenal (HPA) axis can 
also be acutely overstimulated by MDMA, with cortisol levels increasing by up to 
800% in MDMA-using dance clubbers (20). Furthermore the regular use of 
Ecstasy/MDMA can lead to chronic disruptions in the HPA axis. In a recent study we 
collected hair samples from 101 young volunteers, and measured the amount of 
cortisol laid down in their hair over the recent 3 months. The regular users of 
Ecstasy/MDMA displayed a highly significant group mean 400% increase in hair 
cortisol, when compared to non-user controls, whereas the light users showed non-
significant increase of around 50% (21). Cortisol is also known as the ‘stress 
hormone’, and several groups have shown changes in cortisol patterns and/or 
increased stress levels. Scholey et al (25) found that drug free Ecstasy/MDMA users 
reported significantly higher levels of stress, than similar aged non-user controls. 
Wetherell and Montgomery (26) showed that the cortisol awakening response, and 
other indications of cortisol secretion, were altered in drug-free Ecstasy/MDMA 
users, especially under conditions of high environmental stress. The various 
indications of change to the HPA axis have been outlined in recent reviews (27,28), 
while potential neurohormonal topics for future research have also been suggested 
(29).  The contributory role of oxytocin also needs to be further studied, since 
oxytocin may be involved in the positive psychosocial effects of MDMA (30,31). 
Furthermore, nasal oxytocin  may potentially comprise a safer compound for drug 
assisted psychotherapy (30-32,91). 
 
The acute mood effects of MDMA can be extremely euphoric, although as with all 
CNS stimulants, negative moods may also be intensified (34,35).  Several years ago, 
we found that initial MDMA experimenters who stopped taking it reported less 
positive moods, than those who progressed to regular usage (36). An almost identical 
pattern has been found with young cannabis experimenters, since those who reported 
more positive initial responses to cannabis, displayed  a far greater tendency to 
become regular cannabis users (37). Indeed there are a number of interesting 
functional and psychobiological similarities between the sedative drug herbal/spice 
cannabis, and the stimulant drugs MDMA and mephedrone; these were outlined in 
Parrott et al (38). Hence an interesting topic for future research, not just for MDMA, 
but with other recreational drugs such as mephedrone, cocaine or cannabis, is to 
further investigate this individual variation in initial reactions to the psychoactive 
drug. In many studies this variation will be embedded with the overall group values, 
and hence often ignored, yet it may provide a fruitful topic for future research. 
Another related issue is negative mood reactions. Many studies into CNS stimulant 
drugs have focused on positive mood gains, yet negative mood abreactions occur with 
all stimulants - including MDMA (39). It is important for future studies to include 
adverse mood state scales within their assessment batteries, since some past studies 
have only included positive mood scales – and hence found only positive outcomes 
(see review in: 40). 
 
MDMA is a powerful metabolic activator; indeed being a methamphetamine 
derivative, it comes from one of most powerful classes of all recreational stimulant 
drugs. The acute effects of MDMA have been outlined in several reviews (41-44). 
The strong CNS activation it generates is the basis for the Bioenergetic Stress model 
of MDMA, which is described in the following articles (12,14,45-49). The 
Bioenergetic Stress model for humans was based on laboratory animal research 
(50,51). This explanatory model notes that the heightened activation in recreational 
users, will often represent the combined  sympathomimetic overstimulation caused 
directly by MDMA, along with the stimulatory environmental conditions at dance 
clubs (47,52). This model generates a number of interesting questions for future 
research. How do the co-factors of environmental activation: prolonged dancing, loud 
music, social crowding, sweating/dehydration, and body/brain overheating, heighten 
the basic metabolic overactivation caused by MDMA (14,47,49,53,54). What are the 
key individual difference factors, such as personality characteristics or genetic 
profiles, of those who seem most susceptible to this overactivation? Why are females 
more susceptible to the development of acute hyponatraemia (55)? It is also known 
that MDMA causes programmed cell death or apoptosis in laboratory animals, and 
increases oxidative stress in recreational users (56). MDMA has also been tested as 
drug for cancer therapy - due to its ability to damage human cells (see the relevant 
medical papers listed in Parrott (14,49,54). All these factors lead to a number of 
interesting questions for future investigation; more specifically, how are these factors 
related to the acute and chronic psychobiological deficits caused by MDMA.   
 
One of the key concepts behind MDMA research is the notion of ‘serotonergic 
neurotoxicity, which was originally based on extensive animal research (50,57,58; 
many others). The human findings on this  influential concept were the focus for a 
recent review (49).  In the latter paper, it was noted that many neuroimaging studies 
had found reduced levels of the serotonin transporter (SERT), with significant deficits 
found across the whole of the cerebral cortex (e.g. 59-62). In terms of functional 
deficits, lower levels of SERT were correlated with greater neurocognitive 
impairments (60). Many other areas of psychobiological deficit have also been 
empirically revealed; they  include - changes in sleep architecture, sleep apnoea due to 
reduced serotonergic control of breathing, subjective complains of impaired sleep, 
impaired problem solving, reduced social intelligence, reduced everyday task 
performance, physical tremor,  deficits in the visual processing, altered patterns of 
brain activity, increased pain perception, reduced immunocompetence, heightened 
psychiatric distress, and many other problems. There are numerous empirical studies 
describing these deficits (e.g.63-74; many others). For more detailed coverage of the 
many relevant empirical studies, see the following reviews (12,14,43-45,49). Another 
key question is whether these psychobiological deficits recover following drug 
cessation; the limited data from some early studies was outlined in Parrott (12). More 
recently, Taurah et al (75) assessed over 100 former users, and compared them to 
current users, and several non-user control groups. They found that following 
cessation for an average of four years, functional recovery on the test battery was 
minimal, with former MDMA users remaining just as impaired as current MDMA 
users. This suggests that the psychobiological damage caused by MDMA may be 
relatively permanent. This comprises another key area for future research.  
 
The recreational use of Ecstasy/MDMA by pregnant mothers, has also been shown to 
lead to significant psychomotor impairments in the emergent children. This has been 
described in a series of reports, covering the developmental abilities of the children at 
different ages: 4 months, 12 months and 24 months (76-78). This prospective study 
followed an earlier medical report, where congenital defects and cardiac abnormalities 
were found in mothers who had used MDMA recreationally during their pregnancy 
(79). Indeed in the DAISY study, one of the 12 children born to the heavier MDMA-
using  mothers had a rare congenital defect, while there was also significant gender 
bias in birth outcomes, which was not apparent in the polydrug control group. Further 
studies of mothers are obviously required. Drug usage by fathers is another important 
research issue, and it may be a factor of potential interest for sperm donation clinics.   
 
Mephedrone (m-cat) compared to MDMA (Ecstasy)   
 
Mephedrone or meth-cathinone (m-cat) is a member of the cathinone class, with 
psychobiological effects which are more intense than those generated by cathinone 
derived from chewing leaves of the Khat plant (80-83). The stronger effects of 
mephedrone can make its effects similar to those of MDMA in some  ways, although 
different in others. Hence mephedrone and MDMA can lead to positive feelings of 
euphoria and emotional closeness, while they are typically followed by more negative 
feelings of tiredness or depression in the post-drug recovery period. This pattern is 
similar to that found with Khat derived cathinone, and indeed with all other 
recreational stimulant drugs (39,80-83). The recent history of mephedrone, and how it 
how it has become an illicit  recreational  drug during the past 10 years, has been 
outlined in the following articles (84-86). However empirical research on mephedrone 
compares with MDMA is currently very limited (87,88). So that while there has been 
some debate over their similarities and dissimilarities, there is an urgent need for more 
empirical data, especially on functional effects.  
 
In order to address this issue, we recently undertook one comparison study of 
recreational mephedrone and MDMA, and another focused solely on mephedrone. In 
Jones et al (3) 152 Ecstasy/MDMA polydrug users, and 83 mephedrone/m-cat 
polydrug users, were recruited through the Internet. They were asked about the 
average amount of drug taken per session, maximum usage per session, and subjective 
effects across a range of questions. The incidence of many of the subjective effects 
was similar for both drugs, with similar levels of positive moods following acute self-
administration. However mephedrone users reported more severe recovery issues in 
the days following usage, along with more problems with sleep, anger and anxiety. It 
should be noted that these problems were also noted by the Ecstasy/MDMA users, 
confirming previous reports of adverse acute effects and mid-week recovery problems 
(1,2,20,41,42,89). One of the more noticeable differences between these drugs, was 
the lower acute pharmacodynamic tolerance to mephedrone. With MDMA, repeated 
self-dosing over a single time period led to weaker subjective effects – due to ‘acute 
tolerance’. In contrast, mephedrone users reported that repeated self-dosing over a 
single time period led to continued subjective efficacy – hence they tended to take the 
drug for longer periods. This more intensive usage may also help to explain why 
many of the adverse drug effects were comparatively stronger with mephedrone. Our 
second study (4), assessed psychiatric profiles using the Brief Symptom Inventory, 
and the personal drug experiences of mephedrone polydrug users. The psychiatric 
symptom profiles of the mephedrone polydrug users and other polydrug user controls 
were significantly raised, in comparison with the non-user control group. Many 
regular mephedrone users also reported that the come-down effects became 
progressively worse over time, and that they acted as ‘wake-up call’ - for the 
increasing damage to daily living the drug was causing.   
 
In summary, all the recreational CNS stimulants are psychobiologically damaging. 
Indeed the damaging effects of Ecstasy/MDMA are broadly similar to those found 
with established recreational stimulants, such as cocaine, amphetamine and 
methamphetamine (39). As far as we are currently aware, they are also broadly 
similar to those found with the NPS drug mephedrone. However more research needs 
to be conducted into the long-term effects of this novel substance, while similar 
studies are also needed for Khat–chewing and cathinone (82,83).  Hence we need 
more studies into their neurocognitive, psychomotor, visual, neurohormonal, cardiac, 
and psychiatric consequences, to see how they compare with the adverse effects of 
MDMA. Finally, we also need to study the effects of mephedrone and cathinone on 
foetal development - when taken recreationally during pregnancy.   
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